Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with apatinib

BACKGROUND: Hypertension (HTN) is a common adverse event of the vascular endothelial growth factor pathway inhibitor apatinib. This study was conducted to evaluate the association of apatinib-induced HTN with clinical outcomes in patients with advanced non-small-cell lung cancer (NSCLC). METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Shen-Cun, Huang, Wen, Zhang, Ying-Ming, Zhang, Hai-Tao, Xie, Wei-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362948/
https://www.ncbi.nlm.nih.gov/pubmed/30774384
http://dx.doi.org/10.2147/OTT.S189984

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362948/
https://www.ncbi.nlm.nih.gov/pubmed/30774384
http://dx.doi.org/10.2147/OTT.S189984

Ejemplares similares